Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Bolt Biotherapeutics (BOLT) Operating Expenses (2020 - 2025)

Bolt Biotherapeutics' Operating Expenses history spans 6 years, with the latest figure at $9.9 million for Q3 2025.

  • For Q3 2025, Operating Expenses fell 43.86% year-over-year to $9.9 million; the TTM value through Sep 2025 reached $51.1 million, down 40.31%, while the annual FY2024 figure was $80.7 million, 3.97% down from the prior year.
  • Operating Expenses for Q3 2025 was $9.9 million at Bolt Biotherapeutics, down from $11.0 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $27.6 million in Q4 2021 and bottomed at $9.9 million in Q3 2025.
  • The 5-year median for Operating Expenses is $21.9 million (2023), against an average of $20.5 million.
  • The largest annual shift saw Operating Expenses surged 112.59% in 2021 before it crashed 53.86% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $27.6 million in 2021, then decreased by 18.61% to $22.5 million in 2022, then fell by 2.65% to $21.9 million in 2023, then decreased by 22.6% to $16.9 million in 2024, then plummeted by 41.64% to $9.9 million in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Operating Expenses are $9.9 million (Q3 2025), $11.0 million (Q2 2025), and $13.3 million (Q1 2025).